176 related articles for article (PubMed ID: 30724336)
1. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib.
Scarfì F; Melotti B; Veronesi G; Ravaioli GM; Baraldi C; Lambertini M; Patrizi A; Dika E
Australas J Dermatol; 2019 Aug; 60(3):e242-e243. PubMed ID: 30724336
[No Abstract] [Full Text] [Related]
2. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
Zaloum A; Falet JR; Elkrief A; Chalk C
Neurology; 2020 Feb; 94(7):322-323. PubMed ID: 31888971
[No Abstract] [Full Text] [Related]
3. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
Hussar DA; Kaminski JL
J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
[No Abstract] [Full Text] [Related]
4. Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma.
Med Lett Drugs Ther; 2013 Aug; 55(1422):62-3. PubMed ID: 23917385
[No Abstract] [Full Text] [Related]
5. [A woman with a skin lesion suspected for melanoma].
Post NF; Huis In 't Veld E; Crijns MB
Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267633
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
7. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
[No Abstract] [Full Text] [Related]
8. Effective treatment with Dabrafenib and Trametinib for a BRAF-mutated metastatic dedifferentiated malignant spindle cell neoplasm.
Escandell I; Cabezas M; Martín JM; Terradez L; Pinazo MI
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1224-6. PubMed ID: 25917403
[No Abstract] [Full Text] [Related]
9. Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report.
Lim J; Lomax AJ; McNeil C; Harrisberg B
Ocul Immunol Inflamm; 2018; 26(4):628-631. PubMed ID: 27892777
[TBL] [Abstract][Full Text] [Related]
10. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib.
Sawada H; Kanehisa F; Katoh N; Asai J
J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335
[No Abstract] [Full Text] [Related]
11. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
12. GSK drug combination approved for advanced melanoma.
Inman S
Am J Manag Care; 2014 Feb; 20(2 Spec No.):E10. PubMed ID: 25764581
[No Abstract] [Full Text] [Related]
13. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
[TBL] [Abstract][Full Text] [Related]
14. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
15. Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
Laske J; Meier F; Bauer A; Beissert S; Garzarolli M
Melanoma Res; 2018 Oct; 28(5):485-487. PubMed ID: 30148769
[No Abstract] [Full Text] [Related]
16. Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.
Yamazaki N; Tsutsumida A; Takahashi A; Namikawa K; Yoshikawa S; Fujiwara Y; Kondo S; Mukaiyama A; Zhang F; Kiyohara Y
J Dermatol; 2018 Apr; 45(4):397-407. PubMed ID: 29399853
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib/dabrafenib and trametinib.
Rissmann R; Hessel MH; Cohen AF
Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
[No Abstract] [Full Text] [Related]
19. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
20. Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma.
Mistry HB; Orrell D; Eftimie R
Cancer Chemother Pharmacol; 2018 Feb; 81(2):325-332. PubMed ID: 29222604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
